HDAC9

HDAC9

A gene on chromosome 7q21.1 that encodes histone deacetylase 9, a protein with sequence homology to members of the histone deacetylase family and orthologous to Xenopus and mouse MITR genes, the protein product of which lacks a histone deacetylase catalytic domain. MITR represses myocyte enhancer factor-2 (MEF2) activity by recruiting multicomponent corepressor complexes—including CtBP and HDACs. HDAC9 may play a role in haematopoiesis.
Mentioned in ?
References in periodicals archive ?
The primer ser for each gene was followed: histone deacetylase 9 (HDAC9) forward, 5'-GCAAGAGGAGACAGAGACCG-3'; HDAC9 reverse, 5' - ACTTG G C ACTTCAC AAG G CT- 3'; minichromosome maintenance deficient 3 associated protein (MCM3AP) forward, 5'-CGCTTCCTCTGGTGGTTCTT-3'; MCM3AP reverse, 5'CTGCACTGCTTGCAAAACCT-3'; GAPDH forward, 5'-TCACCCACACTGTGCCCATCTATGA-3'; GAPDH reverse, 5'-GAGGAAGAGGATGCGGCAGTGG-3'.
In addition, all compounds affected NF-[kappa]B by regulating HDAC9, MCM3AP, Wilms' tumor 1 (WT1), and Spi-B transcription factor (SP1B) genes in the nucleus.
We quantified the expression levels of HDAC9 and MCM3AP genes because these genes are associated with hepatocarcinogenesis and are directly interacted with NF-[kappa]B (Wang et al.
For examples, HDAC9 is a transcriptional regulator of the histone deacetylase family, which is regulated by Sol and NF-[kappa]B (Ma et al.
Two of the new loci are in or near histone deacetylase genes HDAC4 and HDAC9.
The Mammalian HDAC enzymes The Class I HDACs -HDAC1 and HDAC2 -HDAC3 -HDAC8 -HDAC11 The Class II HDACs - HDAC4 and HDAC5 - HDAC6 - HDAC7 - HDAC9 - HDAC10 The Class III HDACs 7.
His research is focused on the functions of immune T regulatory (Treg) cells and related roles of Class II HDACs, including HDAC6, HDAC7 and HDAC9.
The researchers discovered an alteration in a gene called HDAC9, which affects a person's risk of large artery ischemic stroke.
The protein produced by HDAC9 is already known to play a role in the formation of muscle tissue and heart development.
The next step is to determine in more detail the relationship between HDAC9 and stroke and see whether we can develop new treatments that reduce the risk of stroke.
Interestingly, there are already drugs available which inhibit the HDAC9 protein.